Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes, today announced it has entered into a clinical trial collaboration agreement with Merck. Under this collaboration, Hummingbird ...
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced the appointment of Josh House as Chief Financial Officer, effective immediately. Dr. Piers Ingram, CEO and co-founder of Hummingbird ...
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced that internationally renowned scientist and medical oncologist, Dr. Thomas J Lynch, Jr, MD, has been appointed to its Board ...
Popular Posts
